{"product_id":"penn-medicine-penn-hypertension","title":"Penn Medicine Penn Hypertension, Insulin Resistance, Lipid, and Atherosclerosis Meeting 2025","description":"\u003cul\u003e\n\u003cli\u003ePenn Medicine Penn Hypertension, Insulin Resistance, Lipid, and Atherosclerosis Meeting 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cstrong\u003e+ Include: 18 videos + 17 pdfs, size: 1.5 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Target Audience: cardiologists, endocrinologists, internists, and primary care providers\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003eDate \u0026amp; Location: Friday, September 19, 2025, 8:30 AM – 1:00 PM, Virtual\u003c\/div\u003e\u003cbr\u003eCVD is the leading cause of death in the US. Hypertension and diabetes are among the foremost risk factors for the development of CVD, stroke, peripheral artery disease, and heart attack. This program will provide an overview of recent advances that target the underlying pathophysiology of cardiovascular disease. The focus of the program will be on the new therapeutic strategies for hypertension, hyperlipidemia, and CKD.\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eLearning Objectives\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cem\u003eAfter completing this activity, participants should be able to:\u003c\/em\u003e\n\u003cbr\u003e\n\u003c\/div\u003e\n\u003col\u003e\n\u003cli\u003eSelect appropriate medications to reduce adverse cardiovascular outcomes in high-risk and vulnerable populations\u003c\/li\u003e\n\u003cli\u003eIdentify appropriate blood pressure treatment strategies in high-risk patient populations\u003c\/li\u003e\n\u003cli\u003eReview the controversies regarding novel therapies for CVD prevention.\u003c\/li\u003e\n\u003cli\u003eProvide the best screening options for hypertension\u003c\/li\u003e\n\u003cli\u003eApply appropriate pharmacologic and non-pharmacologic approaches to cardiovascular risk prevention\u003c\/li\u003e\n\u003c\/ol\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003ch3 class=\"boxAgendaTitle\"\u003eFriday, September 19, 2025\u003c\/h3\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"12u\"\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"10u\"\u003e8:15AM – 8:30AM Sign into Virtual Platform\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"10u\"\u003e8:30AM – 8:35AM Welcome \u0026amp; Introductions Debbie Cohen Stein, MD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"12u\"\u003e\n\u003cdiv class=\"boxAgendaTitle\"\u003e\n\u003cdiv\u003eSESSION I: HYPERTENSION UPDATES\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"10u\"\u003e8:35AM – 8:45AM What’s New in Hypertension Guidelines Jordana Cohen, MD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"10u\"\u003e8:45AM – 8:55AM Peripartum Hypertension Management Monika Sanghavi, MD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"10u\"\u003e8:55AM – 9:05AM Optimizing Antihypertensive Treatment Selection in Patients with CKD Matthew Denker, MD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"10u\"\u003e9:05AM – 9:15AM Fibromuscular Dysplasia and Spontaneous Coronary Artery Dissection Jennifer Lewey, MD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"10u\"\u003e9:15AM – 9:45AM Q\u0026amp;A Panel and Case Presentation with the Speakers Hanaro E Lee, CRNP RN (Moderator)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"10u\"\u003e9:45AM – 9:50AM Break\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"12u\"\u003e\n\u003cdiv class=\"boxAgendaTitle\"\u003e\n\u003cul\u003e\n\u003cli\u003eSESSION II: PREVENTIVE CARDIOLOGY – UNDERSTANDING RISK AND EVALUATION\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"10u\"\u003e9:50AM – 10:00AM How Do I Approach Triglycerides? dan E soffer, MD\u003c\/li\u003e\n\u003cli class=\"2u\"\u003e10:00AM – 10:10AM Prediabetes: When to Treat and with What? Benjamin Cooperberg, MD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"2u\"\u003e10:10AM – 10:20AM Advanced Lipid Testing\/Lipoproteins and Discordance Douglas S Jacoby, MD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"2u\"\u003e10:20AM – 10:50AM Q\u0026amp;A Panel and Case Presentation with the Speakers Emma MacAllister, CRNP\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"2u\"\u003e10:50AM – 10:55AM Break\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"2u\"\u003eSESSION III: POTASSIUM AND HYPERTENSION\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"12u\"\u003e\n\u003cul\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e10:55AM – 11:05AM Potassium Management in the Setting of Blood Pressure Medications – When to Check and How to Titrate Accordingly John Demko, MD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"2u\"\u003e11:05AM – 11:15AM Aldosterone Synthase Inhibitors – New Data and Considerations Debbie Cohen Stein, MD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"2u\"\u003e11:15AM – 11:25AM Dietary Potassium and Potassium-based Salt-substitutes Rachel S Shulman, MSCE\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"2u\"\u003e11:25AM – 11:55AM Q\u0026amp;A Panel and Case Presentation with the Speakers Maria L Bonanni, CRNP (Moderator)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"2u\"\u003e11:55AM – 12:00PM Break\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"2u\"\u003eSESSION IV: NOVEL THERAPIES AND INDICATIONS\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"12u\"\u003e\n\u003cul\u003e\n\u003cli class=\"boxAgendaTitle\"\u003e12:00PM – 12:10PM LPa-lowering Drugs Archna Bajaj, MD, MSCE\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"10u\"\u003e12:10PM – 12:20PM GLP1RA\/Incretin Therapy: Updated Indications and Real-World Application Riya Patel, PharmD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"2u\"\u003e12:20PM – 12:30PM Renal Denervation: Management and Setting Expectations Before and After Denervation Taisei Kobayashi, MD\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cul\u003e\n\u003cli class=\"2u\"\u003e12:30PM – 1:00PM Q\u0026amp;A Panel and Case Presentation with the Speakers Gayley B Webb, CRNP RN\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954508271714,"sku":"MED-AMB04959","price":15.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Penn-Medicine-Penn-Hypertension-Insulin-Resistance-Lipid-and-Atherosclerosis-Meeting-2025.jpg?v=1779378473","url":"https:\/\/meducourse.com\/products\/penn-medicine-penn-hypertension","provider":"Meducourse","version":"1.0","type":"link"}